Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 145.57 | 213.74 | 675.16 | 193.23 | 287.02 | 432.97 | 343.17 | 342.39 | 189.59 | 152.63 | 290.95 | 105.96 | 110.11 | 152.03 | 222.04 | 122.16 | 179.39 | 261.74 | 362.21 | 458.67 | 765.75 |
| — | -50.6% | +96.7% | -43.6% | +51.4% | +183.7% | +17.9% | +223.1% | +72.2% | +0.4% | +31.0% | -13.3% | -38.6% | -41.9% | -38.7% | -73.4% | -76.6% | -72.4% | -69.7% | -47.9% | +25.8% | |
| P/B Ratio | 1.65 | 3.35 | 3.19 | 4.14 | 2.82 | 3.58 | 2.11 | 2.49 | 2.53 | 1.90 | 3.92 | 0.95 | 0.80 | 0.76 | 0.76 | 0.59 | 0.59 | 0.79 | 0.82 | 1.74 | 1.97 |
| — | -6.3% | +51.1% | +66.0% | +11.5% | +88.2% | -46.1% | +162.9% | +217.5% | +150.4% | +412.9% | +61.2% | +35.4% | -4.1% | -7.3% | -66.2% | -70.1% | -57.4% | -70.1% | -47.0% | -80.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -9470.2% | 100.0% | 100.0% | -5742.4% | 35.6% | 50.2% | 34.0% | 24.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | +101.1% | 0.0% | 0.0% | +101.7% | -26714.7% | +99.0% | +194.3% | -23914.1% | -64.4% | -49.8% | -66.0% | -75.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -8256.3% | -9245.2% | -31341.5% | -3221.0% | -9978.3% | -12212.4% | -13194.5% | -8325.8% | -7637.0% | -7696.3% | -5333.2% | -6623.1% | -7673.8% | -11303.7% | -14520.5% | -7337.5% | -9669.9% | -11475.8% | -14964.9% | -7162.4% | -8137.2% |
| — | +24.3% | -137.5% | +61.3% | -30.7% | -58.7% | -147.4% | -25.7% | +0.5% | +31.9% | +63.3% | +9.7% | +20.6% | +1.5% | +3.0% | -2.4% | -18.8% | -13.3% | -98.0% | -31.5% | -153.6% | |
| Net Margin | -7732.0% | -8876.9% | -30109.8% | -2969.5% | -9381.7% | -11523.1% | -12324.8% | -7806.0% | -7184.8% | -7225.8% | -4883.4% | -5985.3% | -6901.4% | -10324.1% | -13521.7% | -6794.5% | -9216.1% | -11475.8% | -14855.4% | -7099.2% | -8038.4% |
| — | +23.0% | -144.3% | +62.0% | -30.6% | -59.5% | -152.4% | -30.4% | -4.1% | +30.0% | +63.9% | +11.9% | +25.1% | +10.0% | +9.0% | +4.3% | -14.7% | -15.5% | -106.5% | -28.3% | -143.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -71.5% | -30.1% | -30.8% | -15.3% | -21.0% | -21.5% | -17.5% | -17.8% | -23.3% | -20.8% | -15.3% | -12.7% | -11.8% | -12.2% | -11.1% | -7.9% | -7.3% | -8.3% | -8.1% | -6.9% | -5.1% |
| — | -40.0% | -76.5% | +14.0% | +10.0% | -3.6% | -14.0% | -40.8% | -96.8% | -70.7% | -38.5% | -59.7% | -61.4% | -46.1% | -36.2% | -14.9% | -44.6% | -62.7% | -98.5% | +15.5% | +67.3% | |
| ROA | -57.6% | -21.3% | -22.2% | -11.5% | -16.1% | -17.4% | -14.8% | -14.7% | -18.4% | -16.8% | -12.9% | -11.0% | -10.5% | -10.9% | -10.1% | -7.3% | -6.7% | -7.7% | -7.6% | -6.5% | -4.9% |
| — | -22.9% | -50.6% | +22.0% | +12.2% | -3.3% | -14.8% | -34.1% | -75.6% | -53.8% | -27.6% | -51.4% | -55.7% | -41.6% | -32.3% | -11.7% | -38.7% | -56.2% | -94.3% | +14.3% | +62.5% | |
| ROIC | -118.9% | -32.3% | -34.7% | -17.2% | -20.3% | -22.8% | -26.6% | -26.5% | -28.3% | -25.8% | -17.4% | -13.5% | -12.1% | -11.9% | -10.2% | -7.4% | -6.8% | -7.3% | -6.8% | -5.6% | -4.2% |
| — | -41.7% | -30.5% | +35.4% | +28.4% | +11.5% | -53.2% | -97.2% | -134.7% | -116.5% | -69.8% | -81.6% | -78.7% | -64.0% | -50.7% | -32.4% | -62.3% | -68.4% | +9.5% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -14.8% | -2.7% | -0.2% | -39.4% | -42.5% | -41.7% | -40.4% | +15.8% | +25.0% | +22.8% | +20.7% | +17.2% | +13.9% | +12.0% | +14.9% | +2.3% | +741.1% | +362.9% | +227.6% | -40.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.67 | 3.30 | 3.27 | 3.67 | 4.20 | 4.42 | 6.22 | 7.08 | 4.74 | 4.97 | 5.91 | 7.41 | 9.30 | 10.16 | 12.49 | 14.25 | 14.52 | 15.02 | 20.38 | 22.28 | 27.32 |
| — | -25.4% | -47.4% | -48.2% | -11.3% | -11.1% | +5.3% | -4.5% | -49.1% | -51.1% | -52.7% | -48.0% | -35.9% | -32.3% | -38.7% | -36.0% | -46.8% | -51.8% | -29.0% | +2.2% | +289.4% | |
| Quick Ratio | 3.67 | 3.30 | 3.27 | 3.67 | 4.20 | 4.42 | 6.22 | 7.08 | 4.74 | 4.97 | 5.91 | 7.41 | 9.30 | 10.16 | 12.49 | 14.25 | 14.52 | 15.02 | 20.38 | 22.28 | 27.32 |
| — | -25.4% | -47.4% | -48.2% | -11.3% | -11.1% | +5.3% | -4.5% | -49.1% | -51.1% | -52.7% | -48.0% | -35.9% | -32.3% | -38.7% | -36.0% | -46.8% | -51.8% | -29.0% | +2.2% | +289.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRDF stock.
Cardiff Oncology, Inc.'s current P/E is -1.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cardiff Oncology, Inc.'s current operating margin is -8256.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cardiff Oncology, Inc.'s business trajectory between earnings reports.